Download the Full Event Guide for full session details.
1.30 Panel Discussion: Screening for Toxicity in the Early Studies to Optimize the Design
- Discussing how some linker warhead combinations may work with one antibody but not with another
- Is the combination that you use as a default or is it the most optimal approach
- Looking into conjugation chemistry that should be considered to be tested in early screening
2.00 Mechanisms of Hematological Toxicity of Antibody Drug Conjugates: Role of Drug-load Release
Session Reserved for Mersana
2.30 Analyzing the Impact of the Conjugation Chemistry on Toxicity & Safety Profiles, Analyzing which Warheads are Suitable for Certain Indications & what Toxicity is Acceptable Under Particular Conditions
Session Reserved for AstraZeneca
3.00 Think Tank Roundtable Sessions
More practical and highly interactive breakout roundtables where attendees can crowdsource solutions and share opinions around pre-assigned topic areas. A valuable chance for attendees to unite around hot topics and debate best practice. No more sitting quietly, this is a dedicated opportunity for you to voice your experiences and identify unique solutions.
3.30 Moderator Feedback & Audience Debate
Following the roundtables, moderators will present back to the entire delegation as part of a panel discussion for information dissemination.
Download the Full Event Guide for full session details.
1.30 HPAPIs & ADCs – A Journey Through High Potency
- Case Study: The development, rapid scaling and commercial production of HPAPI drug substance
- Integrated containment requirements for particle engineering and drug products
- Advantages of seamless integration of HPAPI and ADC operations
- Impact of supporting integrated service-offerings on expansion strategies
David Lyon, Senior Fellow, Research Lonza Pharma & Biotech, Lonza
2.00 CMC Strategic Considerations for Advancing ADCto Late Phase Development
- Advancing manufacturing operations to phase II and beyond
- Considerations on CMC strategy for advancing ADCs to late-phase development
- Case study: Process changes and demonstration of comparability
Ying Buechler, Vice President, Development, Ambrx
2.30 What we Learnt from ADCs to Shape Phase ll Manufacturing & Beyond
- Applying engineering tools such as computational fluid dynamics (CFD) simulations to design representative scale down models
- Levering scale down models to accelerate timelines and manager risks
- A case study will be shared detailing an example of an accelerate program and how process characterization timelines were shortened, and risks mitigated by applying these concepts
Dan Milano, Senior Manager, ADC Development & Manufacturing Outsourcing, ImmunoGen
3.00 Think Tank Roundtable Sessions
- More practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre assigned topic areas. A valuable chance for attendees to unite around hot topics and debate best practice. No more sitting quietly, this is a dedicated opportunity for you to voice your experiences and identify unique solutions.
3.30 Moderator Feedback & Audience Debate
Following the roundtables, moderators will present back to the entire delegation as part of a panel discussion for information dissemination.
Download the Full Event Guide for full session details.
1.30 Panel Discussion: What we Have Learnt from Combination Studies & Where do we go Next?
Nick Choong, Executive Director, Seattle Genetics
Daijin Abidoye, Seattle Geneteics
Louie Namauvski, Senior Medical Director, AbbVie
Jay Harper, Associate Director - Research Onocology, AstraZeneca
2.00 ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 & IMFINZI in Multiple Types of Advanced Non-Hodgkin Lymphoma
Session Reserved for ADC Therapeutics
2.30 Role of Protein Engineering & Bioconjugation in Rational Design of Next Generation Nanoparticle Vaccines
- Well-defined biomaterial based nanoparticle as scaffold provides a modular platform to develop vaccines and related immune modulating agents
- Covalent incorporation of antigen proteins and adjuvants using protein engineering and site specific bioconjugation offers well-defined immunoactive nanotherapies with enhanced activity durable response
- In additional to reviewing of the state of the art, case studies focusing on influenza vaccine will be highlighted
- Potential role in developing combination immunotherapy will be highlighted
Pradeep Dhal, Senior Director - Research & Development, Sanofi
3.00 Think Tank Roundtable Sessions
More practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas. A valuable chance for attendees to unite around hot topics and debate best practice. No more sitting quietly, this is a dedicated opportunity for you to voice your experiences and identify unique solutions.
3.30 Moderator Feedback & Audience Debate
Following the roundtables, moderators will present back to the entire delegation as part of a panel discussion for information dissemination.
Download the Full Event Guide for full session details.
1.30 Bioanalytic Strategy for ADCs: Perspectives from IQ ADC WG
- Overview of IQ/OCP meeting on October 2017
- ADC WG database
- Bioanalysis strategy for ADCs
Dong Wei, Associate Director - Bioanalytical, Biomarker, Drug Metabolism & Pharmacokinetics, Takeda
2.00 Control Strategies for ADCs with Multiple MoAs
- ADCs that are able to demonstrate multiple mechanisms of action may have a greater therapeutic benefit
- A robust control strategy is needed to control for MOAs
- We present a case study where acceptance limits on N-linked glycans, drug loading and potency are leveraged to provide effective controls over multiple MoAs
Nomalie Jaya, Director, Product Quality, Seattle Genetics
2.30 Think Tank Roundtable Sessions
More practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas. A valuable chance for attendees to unite around hot topics and debate best practice. No more sitting quietly, this is a dedicated opportunity for you to voice your experiences and identify unique solutions.
3.30 Moderator Feedback & Audience Debate
Following the roundtables, moderators will present back to the entire delegation as part of a panel discussion for information dissemination.